Article Text
Mailbox
PostScript
Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy
Statistics from Altmetric.com
The use of intravitreal Bevacizumab had been considered a first-line therapy in age-related macular degeneration (AMD) treatment until 2 years ago, despite the fact that there were no clinical trials backing it and that Bevacizumab was not created for that purpose. Consequently, Genentech modified the molecule of Bevacizumab, without affecting the basis of its efficacy but with the specific aim of treating this pathology, and so the new drug Ranibizumab was developed. However, no indirect comparisons have revealed any significant differences between both treatments in efficacy.1–3
The …
Footnotes
Competing interests: None.
Linked Articles
- Mailbox